Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards

Teva Confirms September PDUFA Date For Fremanezumab

By Teva Pharmaceutical Industries | May 25, 2018

Teva Pharmaceutical Industries Ltd. has confirmed that the U.S. Food and Drug Administration (FDA) has extended the goal date of the Biologics License Application (BLA) for fremanezumab, an investigational therapy for the preventive treatment of migraine. The Prescription Drug User Fee Act (PDUFA) action date for fremanezumab is set for September 16, 2018.

There are no additional data requests from the FDA, according to Teva.

“Our primary goal is to bring preventive treatment options to migraine patients as quickly as possible,” said Hafrun Fridriksdottir, executive vice president, global R&D at Teva. “We are encouraged by the ongoing communications with the FDA as we work to bring this important therapy to patients.”

Fremanezumab is an investigational therapy currently under review by the FDA as a quarterly or monthly injection for the preventive treatment of migraine in adults. It is a monoclonal antibody targeting the CGRP (calcitonin gene-related peptide) ligand. 

With limited availability of preventive treatment options, fremanezumab represents a potential new option to address a significant unmet medical need.

(Source: Teva Pharmaceutical Industries Ltd.)

Related Articles Read More >

HIV
Injectable anti-HIV therapies could see strong growth
Pfizer-BioNTech vaccine
Pfizer vaccine stable at standard freezer temps, effective with single dose
coronavirus COVID-19 Pfizer
4 things to keep in mind as COVID-19 vaccination efforts scale
Johnson & Johnson
J&J CEO says getting a COVID-19 vaccine could be an annual ritual for years

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Pharmaceutical Processing World
  • Enews Signup
  • Contact Us
  • About Us
  • R&D World
  • DeviceTalks
  • Drug Discovery & Development
  • Drug Delivery Business News
  • MassDevice
  • Medical Design Sourcing

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards